Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
53,136,600
-
Total 13F shares
-
36,433,730
-
Share change
-
-246,311
-
Total reported value
-
$410,607,954
-
Put/Call ratio
-
11%
-
Price per share
-
$11.27
-
Number of holders
-
85
-
Value change
-
-$2,049,707
-
Number of buys
-
26
-
Number of sells
-
48
Institutional Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q4 2022
As of 31 Dec 2022,
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) was held by
85 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,433,730 shares.
The largest 10 holders included
venBio Partners LLC, FMR LLC, Vivo Capital, LLC, ORBIMED ADVISORS LLC, Logos Global Management LP, BlackRock Inc., VANGUARD GROUP INC, EVENTIDE ASSET MANAGEMENT, LLC, Cormorant Asset Management, LP, and Redmile Group, LLC.
This page lists
85
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.